AstraZeneca PLC ADR (AZN)
AstraZeneca PLC ADR is a depositary receipt representing common stock of AstraZeneca PLC, a biopharmaceutical company listed on NASDAQ under the ticker AZN. The underlying issuer is involved in the discovery, development, manufacture, and commercialization of prescription medicines across oncology, cardiovascular, renal and metabolism, respiratory and immunology, vaccines and immune therapies, and rare diseases. Its portfolio includes products such as Tagrisso, Imfinzi, Lynparza, Calquence, Farxiga/Forxiga, Brilinta/Brilique, Symbicort, Fasenra, Tezspire, Ultomiris, and Nexium. AstraZeneca markets its medicines through distributors and local representative offices across the United Kingdom, the Americas, Europe, Asia, Africa, and Australasia. The company also has collaborations with Tempus and Pathos on oncology-related AI model development, and with CSPC Pharmaceutical Group on novel oral drug candidates. AstraZeneca was incorporated in 1992, formerly operated as Zeneca Group PLC, and adopted its current name in 1999. It is headquartered in Cambridge, the United Kingdom.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Market Cap | Free Float / Shares Outstanding | Payout Ratio |
|---|---|---|---|---|---|---|---|
|
NASDAQ-AZN
|
Not available
|
Not available
|
Not available
|
Great
|
259.7 B
|
99.5%
|
52.6%
|
